arrow
V

Víctor Sapena

global clinical statistics department
H指数:17
被引数:1,024

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study

使用CAL/BDP PAD-Cream的依从性影响银屑病头皮治疗的有效性和偏好:来自前瞻性、多中心、观察性PRO-SCALP研究的结果

2026-08-100
OA
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study

使用Tildrakizumab的价值导向常规护理中银屑病患者的自报健康幸福感:IV期POSITIVE研究2年数据

2026-05-120
OAAI
Raising the bar of efficacy in atopic dermatitis: lebrikizumab provides deep clinical and itch responses up to 16 weeks (ADvantage study)

提高特应性皮炎疗效标准:lebrikizumab可提供长达16周(ADvantage研究)的深度临床和瘙痒反应

2025-07-010
OAAI
Lebrikizumab improves quality of life in patients with moderate-to-severe atopic dermatitis inadequately controlled or ineligible for ciclosporin (ADvantage study)

Lebrikizumab改善了不适合或无法使用环孢素治疗的轻至重度特应性皮炎患者的生活质量(ADvantage研究)

2025-07-010
OAAI
Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes

进一步失代偿对失代偿期肝硬化临床阶段生存率的影响: 门脉高压和HVPG变化的作用

2024-04-182
PRE
Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data
2023-12-185
PRE
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso (lo)ne administration

布地奈德作为自身免疫性肝炎患者的一线治疗似乎不如标准泼尼松 (lo)ne给药

2023-01-0316
OA
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

肝癌患者合并SARS-CoV-2感染的结局: 一项国际性、多中心、队列研究

2022-06-2310
OAAI
Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria
2022-06-0811
PRE
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
2022-04-0121
PRE
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

索拉非尼早期腹泻作为考虑向二线药物早期迁移的标志

2021-07-061
OAAI
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity
2021-05-2815
OAAI